全国135家医院糖尿病视网膜病变临床用药分析

Investigation and Analysis of Medications for Diabetic Retinopathy in 135 Hospitals

目的分析国内糖尿病视网膜病变患者的临床用药现状,为临床合理用药提供参考。方法采用分层抽样与整体抽样相结合的二阶抽样方式,对《医院处方分析合作项目》中全国9个地区的135家医院2018年门诊、急诊和病房糖尿病视网膜病变用药相关数据进行统计分析。结果2018年135家医院共使用糖尿病视网膜病变药物17种,使用比例最高的科室为内分泌科,其次为眼科。门诊用药占比73.2%。处方量排名前三位的药物羟苯磺酸钙、甲钴胺及胰激肽原酶占所有17种药物总处方量的81.8%,但除羟苯磺酸钙外,多无充分的循证医学证据,且多为超适应证使用。结论糖尿病视网膜病变临床用药的规范性有待进一步提高。

OBJECTIVE To analyse current situation of clinical drug use in diabetic retinopathy and provide reference for clinical rational drug use.METHODS Two-stage sampling method was adopted which combines stratified sampling and holistic sampling,and conducted statistical analysis was conducted of with the clinical medication related data of diabetic retinopathy in 2018,which including 135 hospitals in 9 cities in"the cooperation project of hospital prescription analysis".RESULTS Seventeen Drugs for diabetic retinopathy were used in 135 hospitals in 2018,endocrinology contributed the most,and followed by ophthalmology,and outpatients accounted for 73.2%.The top 3 most frequently used drugs for diabetic retinopathy are calcium dobesilate,mecobalamin and pancreatic kininogenase,which accounted for 81.8%of the total 17 drugs prescription volume.It is lack of evidence for most drugs except for calcium dobesilate,and off-label use of DR drugs is common.CONCLUSION The standardization of clinical medication for diabetic retinopathy needs to be further improved.